Pulmonary Thromboembolism after Intravenous Immunoglobulin Therapy in Guillain-Barre Syndrome |
Jin-Mo Park1, Nam Kyun Kim2, and Jin-Sung Park3 |
1Department of Neurology, Dongguk University, School of Medicine, Gyeongju, Korea 2Divison of Cardiology, Department of Internal Medicine, Kyungpook National University, School of Medicine, Daegu, Korea 3Department of Neurology, Kyungpook National University, School of Medicine, Daegu, Korea |
Corresponding Author:
Jin-Sung Park ,Tel: +82-53-200-2027, Fax: +82-53-200-2029, Email: jinforeva@gmail.com |
Received December 26, 2015 Accepted May 18, 2016 |
Copyright © 2016 The Korean Society of Clinical Neurophysiology |
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium,
provided the original work is properly cited. |
ABSTRACT |
Intravenous immunoglobulin (IVIG) is a safe treatment to treat various neurological disorders, but fatal thrombotic events as rare complications have been reported. A 54-year-old woman with Guillain-Barre syndrome complained of dyspnea during IVIG treatment. She was finally diagnosed with pulmonary thromboembolism. To the best of our knowledge, this is the first case of pulmonary thromboembolism associated with IVIG treatment in a Korean patient with Guillain-Barre syndrome. |
Key words:
Guillain-Barre syndrome, Intravenous immunoglobulin, Pulmonary thromboembolism |
|
|
|